Hydroxychloroquine-induced retinopathy: A dermatologic perspective

American Journal of Clinical Dermatology

Volumn 7, Issue 3, 2006, Pages 171-175

  Tripp, Jackie M ^a   Maibach, Howard I ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE;

DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG PENETRATION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LUPUS ERYTHEMATOSUS; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETINA INJURY; RETINA MACULOPATHY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ANTIMALARIALS; DRUG MONITORING; HUMANS; HYDROXYCHLOROQUINE; RETINAL DISEASES;

EID: 33744923424     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200607030-00003     Document Type: Review

References (27)

1. Millard T, Hughes G. Antimalarials. In: Wakelin SH, Maibach HI, editors. Handbook of systemic drug treatment in dermatology. London: Manson Publishing Ltd, 2004: 80-7
2. Rees RB, Maibach HI. Chloroquine: a review of reactions and dermatologic indications. Arch Dermatol 1963 Sep; 88: 280-9
3. Callen JP, Camisa C. Antimalarial agents. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. Philadelphia (PA): WB Saunders Company, 2001: 251-68
4. Raines MF, Bhargava SK, Rosen ES. The blood-retinal barrier in chloroquine retinopathy. Invest Ophthalmol Vis Sci 1989 Aug; 30 (8): 1726-31
5. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983 Jul; 75 (1A): 40-5
6. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996 May; 39 (5): 723-31
7. Physicians' desk reference. 58th ed. Montvale (NJ): Thomson PDR, 2004
8. Marmor MF. New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy [letter]. Arthritis Rheum 2003 Jun; 48 (6): 1764
9. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002 Jul; 109 (7): 1377-82
10. Katzung BG. Special aspects of geriatric pharmacology. In: Katzung BG, editor. Basic and clinical pharmacology. 9th ed. New York: McGraw Hill, 2004: 1007-14
11. Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicentre outpatient practice. Arthritis Rheum 1997 Aug; 40 (8): 1482-6
12. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991 Aug; 23 (8): 292-6
13. Weiner A, Sandberg MA, Gaudio AR, et al. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991 Nov; 112 (5): 528-34
14. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity despite normal dose therapy. Ann Ophthalmol 1993 Oct; 25 (10): 385-8
15. Mavrikakis M, Papazoglou S, Sfikakis PP, et al. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996 Mar; 55 (3): 187-9
16. Bienfang D, Coblyn JS, Liang MH, et al. Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol 2000 Nov; 27 (11): 2703-6
17. Warner AE. Early hydroxychloroquine macular toxicity. Arthritis Rheum 2001 Aug; 44 (8): 1959-61
18. Alarcon GS. How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy? [letter] Arthritis Rheum 2002 Feb; 46 (2): 561
19. Easterbrook M. Dosage of hydroxychloroquine should be based on ideal body weight: comment on the letter by Alarcon. Arthritis Rheum 2003 Mar; 48 (3): 863-4
20. Tett SE, Cutler DJ, Day RO, et al. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989 Jun; 27 (6): 771-9
21. Furst DE, Lindsley H, Baethge B, et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum 1999 Feb; 42 (2): 357-65
22. Tett SE, Cutler DJ, Day RO, et al. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1988 Sep; 26 (3): 303-13
23. Tett SE, Cutler DJ, Brown KF. High-performance liquid chromatographic assay for hydroxychloroquine and metabolites in blood and plasma, using a stationary phase of poly(styrene divinylbenzene) and a mobile phase at pH 11, with fluorimetric detection. J Chromatogr 1985 Nov; 344: 241-8
24. Tett SE, Cutler DJ, Beck C, et al. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis: a prospective, dose ranging study. J Rheumatol 2000 Jul; 27 (7): 1656-60
25. Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002 Jun; 46 (6): 1460-9
26. Carmichael SJ, Charles B, Tett SE. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 2003 Dec; 25 (6): 671-81
27. Shroyer NF, Lewis RA, Lupski JR. Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? Am J Ophthalmol 2001 Jun; 131 (6): 761-6